What is APO-Gabapentin?

Category: Prescription Drugs

true

Generic name: Gabapentin

Apo-Gabapentin®, a Canadian brand name for gabapentin, is an anticonvulsant medication used as an adjunct treatment for partial seizures and for the management of postherpetic neuralgia and neuropathic pain.

Reported purpose & perceived effectiveness
Purpose Patients Evaluations Perceived Effectiveness
Fibromyalgia 16 7
Nerve pain (neuralgia) 7 3
Pain 4 3
Epilepsy 2 0
Anxious mood 1 1

Show all 13 reasons taken


  • Major
  • Moderate
  • Slight
  • None
  • Can't tell

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations
Severe
0
Moderate
4
Mild
3
None
6

Commonly reported side effects and conditions associated with APO-Gabapentin

Side effect Patients
Drowsiness 2
Aggressive behavior 1
Blurry vision 1
Constant brain fog 1
Depression in afternoon 1
Dizzy spells 1

Show all 11 reported side effects

Dosages

Based on patients currently taking APO-Gabapentin

Dosage Patients
600 mg three times daily 3
900 mg three times daily 2
300 mg daily 1
900 mg daily 1

Why patients stopped taking APO-Gabapentin

Multiple reasons could be selected

Reason Patients
Side effects too severe 4
Doctor's advice 1
Personal research 1
See all 5 patients who've stopped taking APO-Gabapentin

Duration

Currently taking APO-Gabapentin

Duration Patients
1 - 6 months 1
1 - 2 years 3
2 - 5 years 3

Stopped taking APO-Gabapentin

Duration Patients
Less than 1 month 3
1 - 6 months 1
2 - 5 years 1
Adherence
Adherence Evaluations
Always 8
Usually 3
Sometimes 2
Never taken as prescribed 0
Burden
Burden Evaluations
Very hard to take 0
Somewhat hard to take 2
A little hard to take 4
Not at all hard to take 7
Cost per month
Cost per month Evaluations
$200+ 0
$100-199 0
$50-99 3
$25-49 3
< $25 2
Not specified 5

What people switch to and from

Patients started taking APO-Gabapentin after stopping:

Treatment Patients
Duloxetine (Cymbalta) 1
Gabapentin (Neurontin) 1
Temazepam (Restoril) 1
Last updated:
There are no evaluations for APO-Gabapentin.